Capricor Shares Rise on FDA Review
Capricor Therapeutics shares climbed after the FDA agreed to review new data for its Duchenne muscular dystrophy drug. The agency will extend its decision deadline following the planned submission.
X24 PerspectiveRelated Assets:
X24 Perspective